Life science start-up Actome receives seed funding

The Freiburg-based start-up is developing an analysis tool for proteins. With the help of the start-up financing, it wants to bring the product to market maturity.

Freiburg-based life science company Actome has received seed funding. Founded in 2017, the start-up previously conducted research from the University of Freiburg. Now, Düsseldorf-based biotech investment house B.Value and other unnamed investors are putting money into the start-up. No details are given on the amount of the start-up financing. The money is intended to help Actome build a business and develop initial products to market readiness.

Actome develops analytical tools for the life sciences. The first products will help researchers measure proteins and protein interactions in biological samples with unprecedented sensitivity and specificity. Proteins control and direct biological processes through their interactions - known as the interactome - through which they determine our health and well-being. With Actome's technology, researchers will be able to understand these interactions even better. This will change medical diagnostics in an unprecedented way, says Csaba Jeney, co-founder and CEO, about the technology he invented and patented. If this succeeds, it will be possible to develop more personalized medical products than before.